How many years should you take Olaparib?

In patients with newly diagnosed advanced ovarian cancer and those withBRCA mutations, maintenance treatment with olaparib improves overall survival. According to the prescribing information of Lynparza, treatment of breast and ovarian cancer approved for treatment with Lynparza can be continued until disease progression, unacceptable toxicity, or completion of 2 years of treatment.

In a double-blind Phase III clinical trial, patients with newly diagnosed ovarian cancer and BRCA mutations (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive olaparib or placebo for up to 2 years. Prespecified analyzes were performed on overall survival after 7 years of follow-up. Overall, 67.0% of patients who received olaparib survived, compared with 46.5% of patients who received placebo. A new diagnosis of myelodysplastic syndrome or acute myeloid leukemia occurred in 1.5% of patients in the olaparib group compared with 0.8% in the placebo group. No new security signals were detected. This is the longest follow-up of a PARP inhibitor in first-line therapy and reveals a clinically meaningful improvement in overall survival in patients treated with olaparib.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.